Skip to main content

Global Immuno-Oncology Market to Grow at 21% CAGR, Powered by Precision Oncology by 2030

 


The global immuno-oncology market is set to witness a growth rate of 21% in the next 5 years. Increasing incidence and prevalence of cancer, advancements in immunotherapy and personalized medicine, favorable regulatory support and approvals, growing investment in cancer immunotherapy R&D, and expanding applications beyond traditional indications are some of the key factors driving the immuno-oncology market.

Immuno-oncology is a rapidly evolving field of cancer treatment that harnesses the body's immune system to recognize, attack, and eliminate cancer cells. Unlike conventional therapies like chemotherapy and radiation, which directly target tumors, immuno-oncology therapies enhance the immune response against cancer. Key approaches include immune checkpoint inhibitors like PD-1/PD-L1 inhibitors, CAR-T cell therapy, bispecific antibodies, and cancer vaccines. These therapies have revolutionized cancer care by offering durable responses and improved survival in various malignancies. Ongoing research focuses on enhancing efficacy, overcoming resistance, and expanding applications to more cancer types through combination strategies and personalized medicine approaches.

Download a free sample report now 👉
https://meditechinsights.com/immuno-oncology-market/request-sample/

Increasing incidence and prevalence of cancer to propel market demand

The rising global incidence and prevalence of cancer are major drivers of the immuno-oncology market. With cancer being a leading cause of death worldwide, the demand for advanced, effective treatments is growing. . According to the WHO In 2022, there were an estimated 20 million new cancer cases and 9.7 million deaths, and the cancer cases are expected to increase significantly due to aging populations, lifestyle changes, and environmental factors. And, over 35 million new cancer cases are predicted in 2050, a 77% increase from the estimated in 2022 The increasing cases of lung, colorectal, breast, and prostate cancers necessitate innovative therapies like immune checkpoint inhibitors, CAR-T cell therapies, and cancer vaccines. Additionally, aging populations and lifestyle factors, such as smoking and obesity, contribute to higher cancer rates, further driving market expansion. As a result, pharmaceutical companies are investing heavily in immuno-oncology research to develop novel, targeted therapies that improve patient outcomes and survival rates.

Advancements in Immuno-Oncology Products: Emerging Therapies and Future Opportunities

The immuno-oncology field is advancing rapidly, with recent FDA approvals of bispecific T-cell engagers (BiTEs) and renewed interest in cancer vaccines, particularly mRNA-based therapies. Cell therapies, including CAR-T, are expanding into new indications and earlier treatment lines, such as non-Hodgkin’s lymphoma (NHL). Bispecific antibodies offer a promising approach by combining T-cell redirection with checkpoint modulation, potentially overcoming T-cell exhaustion. Additionally, dual-targeting immune checkpoint inhibitors (ICIs) may enhance efficacy over traditional combinations. Innovations in modifying the tumor microenvironment to counteract resistance present significant opportunities for the immuno-oncology market, driving new therapeutic strategies and improved patient outcomes.

Competitive Landscape Analysis

The global immuno-oncology market is marked by the presence of established and emerging market players such as Bristol-Myers Squibb Company, Novartis AG, F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., AstraZeneca, Sanofi, Moderna, Inc., GSK plc, AbbVie Inc., and Merck & Co., Inc.; among others. Some of the key strategies adopted by market players include new product development, strategic partnerships and collaborations, and geographic expansion.

Download a sample report for in-depth competitive insights
https://meditechinsights.com/immuno-oncology-market/request-sample/

Market Segmentation

This report by Medi-Tech Insights provides the size of the global immuno-oncology market at the regional- and country-level from 2023 to 2030. The report further segments the market based on therapy type, cancer type, end user.

  • Market Size & Forecast (2023-2030), By Therapy Type, USD Million
    • Immune Checkpoint Inhibitors (ICIs)
    • CAR-T Cell Therapy
    • Cancer Vaccines
    • Bispecific Antibodies
    • Monoclonal Antibodies
    • Oncolytic Viruses
    • Cytokine Therapy
    • Others
  • Market Size & Forecast (2023-2030), By Cancer Type, USD Million
    • Lung Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Prostate Cancer
    • Melanoma
    • Ovarian Cancer
    • Others
  • Market Size & Forecast (2023-2030), By End User, USD Million
    • Hospitals & Cancer Treatment Centers
    • Specialty Clinics
    • Others
  • Market Size & Forecast (2023-2030), By Region, USD Million
    • North America
      • US
      • Canada
    • Europe
      • UK
      • Germany
      • France
      • Italy
      • Spain
      • Rest of Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • Rest of Asia Pacific
    • Latin America
    • Middle East & Africa

About Medi-Tech Insights

Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services in the areas of market assessments, due diligence, competitive intelligence, market sizing and forecasting, pricing analysis & go-to-market strategy. Our methodology includes rigorous secondary research combined with deep-dive interviews with industry-leading CXO, VPs, and key demand/supply side decision-makers.

Contact:

Ruta Halde
 Associate, Medi-Tech Insights
 +32 498 86 80 79
 info@meditechinsights.com 

Comments

Post a Comment

Popular posts from this blog

Digital Pharmaceutical Supply Chain Management Market Sees Increasing Demand with 9% CAGR Until 2030

  The   digital pharmaceutical supply chain management market is projected to grow at a CAGR of 9% from 2025 to 2030.  The growth is driven by the increasing need for enhanced supply chain transparency, demand for temperature-sensitive drug handling, and the shift towards digitization in healthcare operations. However, the high implementation cost and data privacy concerns are notable restraints. The digital pharmaceutical supply chain management includes integration of advanced technologies like AI, blockchain, IoT, and data analytics into the pharmaceutical supply chain. This integration enhances transparency, efficiency, and traceability across sourcing, manufacturing, and distribution processes. The market is vital for ensuring drug safety, mitigating counterfeiting risks, and optimizing logistics. These solutions also aid in regulatory compliance by offering real-time insights and data for reporting. 🔗 Want deeper insights? Download the sample report here: h...
Post a Comment
Read more

Contrast Media APIs Market Evolving Healthcare Needs and Future Business Prospects CAGR 5% by 2030

  The global contrast media APIs market is set to witness a growth rate of 5% in the next 5 years.  Rising volume of diagnostic imaging procedures; technological advancements in imaging modalities; expansion of healthcare infrastructure in emerging markets; rising R&D investments to develop safer and more effective contrast agents, are some of the key factors driving the contrast media APIs market. Contrast media APIs are the primary compounds used in the formulation of contrast agents, which enhance the visibility of internal structures in diagnostic imaging. These APIs play a crucial role in modalities like  computed tomography  (CT),  magnetic resonance imaging  (MRI), and ultrasound by improving the differentiation between tissues, organs, and blood vessels. Typically derived from iodine or gadolinium, they are formulated to ensure solubility, stability, and patient safety during procedures. The manufacturing of contrast media APIs involves stric...
Post a Comment
Read more

Global Healthcare Payer Services Market: AI, Big Data & 8% CAGR Growth Forecast by 2030

  The healthcare payer services market is expected to grow at a CAGR of approximately 8% from 2025 to 2030.  Key drivers include the rising demand for cost-effective healthcare solutions, increased adoption of digital platforms, regulatory changes mandating operational transparency, the surge in healthcare data, and the growing need for fraud prevention mechanisms. However, challenges such as data security concerns and integration complexities act as significant restraints. The healthcare payer services market encompasses a range of administrative, operational, and financial services provided to healthcare payers, including insurance companies, government agencies, and employer groups. These services aim to enhance efficiency, reduce costs, and improve customer satisfaction. Offerings include claims processing, member management, provider management, and analytics for decision-making. The market leverages advanced technologies such as artificial intelligence and cloud compu...
Post a Comment
Read more